Selected article for: "disease prevent and effective vaccine"
Author: Graham, Barney S.; Anderson, Larry J.
Title: Challenges and Opportunities for Respiratory Syncytial Virus Vaccines
  • Cord-id: 0u5ot5h4
  • Document date: 2013_5_24
    • ID: 0u5ot5h4
    Snippet: Respiratory syncytial virus (RSV) causes a significant proportion of the global burden of respiratory disease. Here we summarize the conclusions of a series of chapters written by investigators describing and interpreting what is known about the virology, clinical manifestations, immunity, pathogenesis, and epidemiology of RSV relevant to vaccine development. Several technological and conceptual advances have recently occurred that make RSV vaccine development more feasible, and this collected k
    Document: Respiratory syncytial virus (RSV) causes a significant proportion of the global burden of respiratory disease. Here we summarize the conclusions of a series of chapters written by investigators describing and interpreting what is known about the virology, clinical manifestations, immunity, pathogenesis, and epidemiology of RSV relevant to vaccine development. Several technological and conceptual advances have recently occurred that make RSV vaccine development more feasible, and this collected knowledge is intended to help inform and organize the future contributions of funding agencies, scientists, regulatory agencies, and policy makers that will be needed to achieve the goal of a safe, effective, and accessible vaccine to prevent RSV-associated disease.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory and additional vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute respiratory and adenovirus vector: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and adequately assess: 1, 2
    • acute respiratory and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and live virus infection: 1, 2, 3, 4, 5
    • acute respiratory and low airway: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory illness and additional vaccine: 1, 2, 3
    • acute respiratory illness and live virus: 1
    • additional target and live virus: 1
    • additional vaccine and adenovirus vector: 1
    • additional vaccine and live virus: 1, 2
    • adenovirus vector and live virus: 1, 2, 3, 4, 5, 6, 7, 8